ADA Scientific Sessions 2026 Abstract

Novel Oral Brain Penetrant NLRP3 Inhibitor PSTC2501 for Treatment of Obesity and Cardiovascular Diseases

By Zhichao Wang, Tao Yu, Zhenzhen Zhu, Shuhui Chen

Experiments in animalsInterventions

The paper

Zhichao Wang, Tao Yu, Zhenzhen Zhu, Shuhui Chen

Shanghai

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1772-P

doi.org/10.2337/db26-1772-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial